Published on 25 Mar 2024 on Benzinga
Wells Fargo upgraded GoodRx Holdings Inc GDRX, noting 2024 guidance has good visibility with upside potential to both estimates & valuation multiples.
Wells Fargo analyst anticipates that GoodRx’s EBITDA margins could surpass expectations in 2025, suggesting a favorable outlook for the company.